Lisinopril

Treats hypertension. ANDA 76059, held by Watson Labs. Lisinopril.

As of Nov 14, 2026, ANDA 76059 (Lisinopril), held by Watson Labs, was first approved by FDA on Jul 1, 2002, with 6 approved supplements and 0 published complete response letters.

First approved: Jul 1, 2002
Supplements approved: 6
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

Lisinopril tablets are an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older Adjunct therapy for heart failure Treatment of Acute Myocardial Infarction 1.1 Hypertension Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 7 submissions below

Date	Submission	Status	Documents
Jul 1, 2002	Original application	Approved	Letter

Products

6 strengths and forms


Lisinopril2.5MG · tablet;oral	Lisinopril	Rx
Lisinopril5MG · tablet;oral	Lisinopril	Rx
Lisinopril10MG · tablet;oral	Lisinopril	Rx
Lisinopril20MG · tablet;oral	Lisinopril	Rx
Lisinopril30MG · tablet;oral	Lisinopril	Rx
Lisinopril40MG · tablet;oral	Lisinopril	Rx

All 7 submissions, including labeling and manufacturing supplements


Aug 14, 2013	Supplement 46Labeling · Standard review	Approved	None posted
Feb 20, 2013	Supplement 43Labeling · Standard review	Approved	None posted
Feb 20, 2013	Supplement 44Labeling · Standard review	Approved	None posted
Jan 23, 2009	Supplement 27Labeling	Approved	None posted
May 8, 2008	Supplement 25Labeling	Approved	None posted
Jan 19, 2006	Supplement 15Labeling	Approved	None posted
Jul 1, 2002	Original application	Approved	Letter

Identifiers

Application: ANDA 76059
Drugs@FDA: Overview at FDA
Company: Watson Laboratories

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters